CryoLife, Inc. (CRY) News
Filter CRY News Items
CRY News Results
|Loading, please wait...|
CRY News Highlights
- For CRY, its 30 day story count is now at 2.
- Over the past 4 days, the trend for CRY's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DECK are the most mentioned tickers in articles about CRY.
Latest CRY News From Around the Web
Below are the latest news stories about Cryolife Inc that investors may wish to consider to help them evaluate CRY as an investment opportunity.
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it was renaming and rebranding itself to Artivion, Inc., effective immediately. Derived from the words "aorta", "innovation", and "vision", the company's new name and brand reflect its evolution to focus on providing innovative technologies to surgeons who treat patients with aortic disease. In conjunction with these changes, effective January 24, 2022, the company will also
The following slide deck was published by CryoLife, Inc. in conjunction with this event....
It is hard to get excited after looking at CryoLife's (NYSE:CRY) recent performance, when its stock has declined 13...
CryoLife to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics, and Digital Health & Services Forum
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that members of management will host one-on-one meetings at the upcoming Canaccord Genuity MedTech, Diagnostics, and Digital Health & Services Forum on Thursday, November 18, 2021. Due to the format of this event no webcast will be available.
The mean of analysts' price targets for CryoLife (CRY) points to a 50.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
This is Pat Mackin CEO of CryoLife. The On-X product line growth was led by the On-X aortic valve revenue growth in North America, which grew 16% compared to 2019. Second, our cardiac tissue declined 10% in the third quarter compared to 2019, resulting from a backlog in review of donor and tissue charge to release this tissue, which, as you will recall, had been temporarily quarantine as a result of our previously discussed Tris issue.
CryoLife (CRY) delivered earnings and revenue surprises of 420.00% and -0.95%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
CryoLife (CRY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoLife (NYSE:CRY) shareholders have endured a 33% loss from investing in the stock three years ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But the risk of stock...
CryoLife Announces Release Date and Teleconference Call Details for Third Quarter 2021 Financial Results
CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2021 financial results will be released on Thursday, November 4, 2021 after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question and answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of CryoLife, Inc.